Anti‐thymocyte Globulin and Post‐Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen‐A and ‐B mismatched donors-Reference-Cited by-同舟云学术

Anti‐thymocyte Globulin and Post‐Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen‐A and ‐B mismatched donors

Published:2021-12-27 Issue: Volume: Page:
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Novitzky‐Basso Igor¹^ORCID,Remberger Mats²^ORCID,Chen Carol¹,Ellison Cynthia¹³,Pasic Ivan¹³^ORCID,Lam Wilson¹³,Law Arjun¹³,Gerbitz Armin¹³,Viswabandya Auro¹³,Lipton Jeffrey H.¹³^ORCID,Kim Dennis D.¹³^ORCID,Kumar Rajat¹³,Michelis Fotios V.¹³^ORCID,Mattsson Jonas¹³⁴

Affiliation:

1. Hans Messner Allogeneic Transplant Program Princess Margaret Cancer Centre Toronto Ontario Canada

2. Department of Medical Sciences Uppsala University and KFUE Uppsala University Hospital Uppsala Sweden

3. University of Toronto Toronto Canada

4. Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation Department of Medicine University of Toronto Toronto Canada

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13735

Reference36 articles.